Merck's full-year 2025 revenue guidance fell short of what some analysts were expecting, at a range of $64.1 billion to $65.6 ...

Thank you for reading & participating. Spout Off is funded by advertising. Please disable or pause your ad blocker to continue.

Merck (NYSE: MRK) recently released its Q4 results, with revenues and earnings exceeding the street estimates.

The global Diabetes Drugs Market size was valued at USD 84.65 billion in 2024 and is expected to be worth around USD 177.74 ...

Merck shares tumbled Tuesday morning after the drugmaker's soft outlook outweighed fourth-quarter revenue and adjusted ...

因为这颠覆了美国创新药市场，延续数十年的“高定价-长周期”商业模式。医保支付方与制药巨头的力量天平开始倾斜。而对于那些依赖单一爆品支撑的药企，正被迫在创新效率和成本控制间走钢丝。

GLP-1 receptor agonists were more cardioprotective in younger people, but reduced HbA1c more with age. The age of type 2 ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will be subject to the next round of Medicare price negotiations, the Biden ...

MRK provided 2025 adjusted EPS guidance of $8.88 to $9.03, while the giant drugmaker expects sales of $64.1 billion to $65.6 ...

The IRA measure is a good first step, but some are looking even further ahead to GLP-1 price drops to increase access.